The large majority of patients with cytogenetically normal AML will now have one or more discernable recurrent genetic mutations. Risk-adapted therapy has allowed for the beginnings of ...

Acute myeloid leukemia (AML) is a highly aggressive and difficult-to-treat blood cancer. This study explores the role of ...

https://www.uksh.de/Das+UKSH/Presse/Presseinformationen/2025/Personalisierte+The... https://tu-dresden.de/med/mf/die-fakultaet/newsuebersicht/personalisierte-therap ...

The first clinical trial under the Cooperative Research and Development Agreement with the National Cancer Institute and ...

Having two copies of the MTHFR gene mutation may raise your risk for certain health conditions, though more research is needed. You may have the mutation and not find out unless you undergo ...

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it will participate at the 37th Annual Roth ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Research led by York University's Faculty of Health reveals how a specific mutation in a protein called TRAF1 can shut down ...